NASA’s COVID-19 ventilator gains FDA approval for emergency use
The Food and Drug Administration yesterday approved for emergency use a ventilator specially developed by the National Aeronautics and Space Administration to treat COVID-19 patients.
NASA’s VITAL (Ventilator Intervention Technology Accessible Locally) system is designed to last three to four months and is specifically tailored for patients with COVID-19 by providing respiratory support for patients experiencing respiratory failure or insufficiency.
Additionally, the device is designed to be built with components outside the current medical device supply chain and thereby will not impact existing ventilator supply chains.
Related News Articles
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…